ERBB2 and breast cancer: Among patients with metastatic HR-positive/HER2-negative breast cancer, ET is usually recommended as initial treatment for breast cancer that is not rapidly progressing and has no visceral metastases, and chemotherapy is usually recommended as initial treatment for breast cancer that shows rapid progression, visceral metastasis, and/or de novo ET resistance.